• Overview
  • Eligibility
  • More info
  • Locations

A Phase II Trial of Pyrazoloacridine (NSC 366140, IND 36325) in Metastatic Cutaneous and Ocular Melanoma (NCT00003802)

National Cancer Institute (NCI)
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of pyrazoloacridine in treating patients who have metastatic skin or eye melanoma.
  • Drug: pyrazoloacridine
    Ages eligible for Study
    18 Years and older
    Genders eligible for Study
    All
    Accepts Healthy Volunteers
    No
    OBJECTIVES:

    - Assess the antitumor activity of pyrazoloacridine (PZA) in chemotherapy naive patients with metastatic cutaneous or ocular melanoma.

    - Determine the toxic effects of PZA in this patient population.

    - Determine the pharmacokinetic profile of PZA in these patients.

    OUTLINE: Patients are stratified into cutaneous or ocular melanoma treatment groups.

    Patients receive pyrazoloacridine IV over 3 hours on day 1. Treatment continues every 21 days in the absence of disease progression or unacceptable toxicity.

    PROJECTED ACCRUAL: Approximately 28-70 patients will be accrued for this study.

    1 locations

    United States (1)
    • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
      Not specified
      Baltimore, Maryland, United States, 21231-2410
    Status:
    completed
    Type:
    Interventional
    Phase:
    Start:
    31 January, 1999
    Updated:
    11 December, 2012
    Participants:
    0
    A girl giving information about available additional trials.

    FindMeCure helps you find, understand and join clinical trials from all over the world.

    There are more clinical trials for your condition!